The Biologics Price Competition and Innovation Act (BPCIA) has been considered overly complex and unclear as to many of its procedural requirements. The US Supreme Court is now considering the Federal Circuit Court’s decision in Amgen v Sandoz, which held that a biosimilar applicant could choose to opt out of the so-called patent dance and that the biosimilar’s notice of commercial launch may only be given after the FDA approves the biosimilar’s application. The Supreme Court’s decision in the case, expected by July, could set a precedent on whether the patent-dance exchange of patent and manufacturing information before FDA approval is necessary and whether biosimilar manufacturers must obey the provision specifying notice of commercial marketing, which effectively adds 6 months to the wait to market the drug after FDA approval.
One of the big questions biosimilar applicants have had to decide upon is whether to engage in the patent dance at all, and if so, for how long. The procedure takes approximately 6 months to complete, representing a significant delay in commercial launch. Another issue has been when to give the reference drug sponsor (RDS) the 180-day notice of commercial launch required by the BPCIA, which represents another 6 months of delay (and is the reason applicants have been trying different ways to give notice as soon as possible; see Amgen v Apotex below). RDSs have also been uncertain about these steps and whether they have the right to seek legal means of forcing biosimilar applicants to comply with the steps.
To date, companies have used 3 main strategies to address the patent dance, according to an analysis in Bloomberg Law Life Sciences Law & Industry Report.
There are still many open questions in the area of biosimilars litigation that the Supreme Court and Federal Circuit Court will continue to weigh in on, and the answers they provide will have significant impact for biosimilar applicants going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.